LGD-4033, originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer, is promoted as a selective non-steroidal anabolic agent. It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use.
However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown. It should be noted that a number of Selective Androgen Receptor Modulators (SARMs) have associated health-risks, particularly for the heart and liver.
Related substances
- Di-hydroxy LGD-4033, (Ligandrol)
- Di-hydroxy LGD-4033 (metabolite of LGD-4033 (Ligandrol))
- LGD-4033 (Ligandrol) and its metabolite Di-hydroxy LGD-4033